FedEx Q4 Results Beat Street View

Package delivery giant FedEx Corp. (FDX), Thursday reported a fourth-quarter profit and revenues that trumped Wall Street estimates, driven by increase in volumes.

Memphis, Tennessee-based FedEx reported fourth-quarter profit of $1.87 billion or $6.88 per share, compared to last year's loss of $334 million or $1.28 per share.

Adjusted earnings for the quarter were $5.01 per share, up from $2.53 per share last year. On average, 26 analysts polled by Thomson Reuters expected earnings of $4.99 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter rose to $22.6 billion from $17.4 billion last year. Wall Street analysts had a consensus estimate of $21.51 billion.

Operating margin improved to 7% from 3.5% last year.

FedEx said its fourth-quarter results were driven largely by volume growth and disciplined revenue and portfolio management. However, this was partially offset by costs to support strong demand, increased variable compensation expense, and higher labor rates.

Looking forward to full year 2020, the company expects adjusted earnings of $20.50 to $21.50 per share. That is before MTM retirement plan accounting adjustments and excluding estimated TNT Express integration expenses and various realignment costs. Analysts currently expect earnings of $20.37 per share.

FDX closed Thursday's trading at $303.69, up $6.32 or 2.13%, on the NYSE. The stock, however, slipped $12.55 or 4.13%, in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT